Friday, October 8, 2021

Investment Climate October 2021: Interesting Times




Markets spent the last quarter in a general “holding pattern with periods of severe up and down volatility followed by periods of relative quiet, all accompanied by low volume and ending with little progress overall for the quarter, which ended flat to slightly down.  Our portfolios acted similarly.  As we are now in the traditionally weak part of the year – September/October – it would not be at all surprising to see a more severe correction materialize, along the lines of 10-15% down.    


There is very little to be pleased with from a policy standpoint in the current climate.   The printing presses have been in full operation at the U.S. Federal Reserve (the Fed) The U.S. Congress and Executive Branch seem determined to deliver a massive tax and spending plan totaling over $5 Trillion (adding to the $4 Trillion or so they have already spent during the era of COVID) And restrictions on virtually every aspect of life on the planet either continue or are threatened to be resurrected at a moments notice.   


In our view, none of this is necessary  so much so that we hold out hope that much of it will fail to materialize, at least the taxing and spending part.  Nonetheless, massive damage has been done to businesses (particularly small ones) due to misguided policies from governments all over the world. Of course, these policies were enacted in the interesof fighting what was considered a serious virus.  However, the impact of these actions is now far more serious than the virus itself.  We did warn of this potential back in March of 2020 in our blog post, “Time For A Pushback.   We urge readers to review that post.  


Regardless, this scenario is what we must deal with at present.  Supply chains are in shambles as the powers-that-be are learning that you cannot turn the economy off and on like a light switch.  Whatever the masters at the Fed say, this situation is not just transitory.  These massive actions have served to disrupt supply chains for years.  And the inflation that everyone is experiencing is likely here to stay, at least for a while.  As for the  damage this has done on a societal level, and how that affects economic behavior going forward, we can only guess.  We expect it will be long-lasting if not permanent. 


Nonetheless, it will be the entrepreneurial drive of the people who run businesses that will lead us out of the morass that has been created.  And good news on that front is at hand.  The long, dark slog of the “8000 to 4000” problem (the drop in the number of public companies on U.S. exchanges), of which we have written about endlessly in recent years, has reversed.  Thanks to the little understood special purpose acquisition company (SPAC), we are now back up to over 5800 companies on U.S. exchanges.  This is amazing news.  These are the generally smaller companies that in the previous 15-20 years were unable to gain access to the capital in public markets, allowing the oligarchic rise of the “FANGS” to dominate the past decade and, in our view, stultify innovation and competition in ways that have become detrimental to economic progress.   


It is from these ranks, and from other companies yet to become public, that we will see the unleashing of the innovation necessary to drive the economy of the 21st century. While some pundits have argued that the technology boom of the past few decades has run its course and is running out of steam, they could not be more mistaken. We are actually on the verge of revolutionary new developments in many areas, among them two important related developments: blockchain technology and distributed computing. This economy will be transformed by the rise of distributed computing tied to blockchain technology and, as our friend George Gilder wrote about in Life After Google, those transformations will power the next generation of computing and technology, not to mention almost every other sector in the economy.  The “central control” of everything from computing to finance will be upended.   


We are reminded of the experience of the 1970s, during which we saw tremendous economic and political mistakes, leading to all kinds of negative consequences (including the rise of enormous conglomerated business behemoths and all kinds of obstacles for smaller companies), but during which we also saw the rise of new and innovative companies (including Apple, Microsoft, Intel, and many others) who would go on to change the world in completely unforeseen ways. We are convinced that the lesson for investors is that we must always be searching for innovative, growing companies and new transformative paradigms (which are at the heart of our narrative-based investment philosophy), no matter how negative the general climate seems to be at any given moment.  Yes, indeed, we are living in interesting times!  Stay tuned. 








Disclosures: Please remember that past performance may not be indicative of future results. Different types of investments involve varying degrees of risk, and there can be no assurance that the future performance of any specific investment, investment strategy, or product (including the investments and/or investment strategies recommended or undertaken by Taylor Frigon Capital Management LLC (“Taylor Frigon”), or any non-investment related content, made reference to directly or indirectly in this blog will be profitable, equal any corresponding indicated historical performance level(s), be suitable for your portfolio or individual situation, or prove successful. Due to various factors, including changing market conditions and/or applicable laws, the content may no longer be reflective of current opinions or positions. Moreover, you should not assume that any discussion or information contained in this blog serves as the receipt of, or as a substitute for, personalized investment advice from Taylor Frigon. To the extent that a reader has any questions regarding the applicability of any specific issue discussed above to his/her individual situation, he/she is encouraged to consult with the professional advisor of his/her choosing. Taylor Frigon is neither a law firm nor a certified public accounting firm and no portion of the blog content should be construed as legal or accounting advice. A copy of the Taylor Frigon’s current written disclosure Brochure discussing our advisory services and fees is available upon request. If you are a Taylor Frigon client, please remember to contact Taylor Frigon, in writing, if there are any changes in your personal/financial situation or investment objectives for the purpose of reviewing/evaluating/revising our previous recommendations and/or services, or if you would like to impose, add, or to modify any reasonable restrictions to our investment advisory services.

Wednesday, October 6, 2021

Have you heard of this company? Codexis (CDXS)
















image: Codexis company website.

At Taylor Frigon Capital, we practice what we describe as a "narrative-based investment philosophy," in which we identify specific macro-trends shaping the direction in which certain businesses or industries or even society in general are moving, and the "narratives" or story-lines which describe what we believe will take place over the next several years in specific industries based on those driving forces.

One of our important investment narratives involves the application of the incredible advances in technology in novel ways to industries outside of what we traditionally think of as "tech" -- and an important aspect of that narrative specifically includes the application of massive computational advances to drive advancements in biology and chemistry.

California-based Codexis, Inc. (ticker CDXS)* is a company we identified as fitting this narrative, and which we own for our investors. Codexis is using advances in computational power, machine-learning algorithms, and lab equipment to analyze proteins and to discover and synthesize new biological enzymes (the proteins which act as catalysts in the body or in biological reactions)  for applications in a variety of industries, including the manufacture of pharmaceuticals, the flavoring of food, and the treatment of disease.

Proteins are chains composed of between 200 blocks of amino acids (at the low end) to over a thousand blocks of amino acids (at the higher end). Each block in these enormous chains can use one of twenty different amino acids in living organisms, creating an almost infinite number of possible combinations. A protein chain of 500 amino acids, with twenty to choose from at each block, could conceivably have permutations which would number -- not 20 times 500 -- but rather 20 raised to the power of 500! 

There are thus nearly infinite numbers of alterations that can be conceived for every known protein -- and while the majority of these alterations are not helpful in achieving a function that may be desired for creating some type of reaction, some of these permutations will enable the engineering of enzymes that can do things which are extremely beneficial, and even life-saving.

Since 2002, Codexis has been perfecting their proprietary CodeEvolver protein engineering technology platform which allows increasingly accurate predictions for the properties of different possible protein permutations, while also building an ever-growing library of protein variants and their various properties and capabilities. They license this technology to industry partners, as well as using it to develop their own novel enzymes for various applications, including for therapies to treat inherited disorders in which certain enzymes are deficient.

A large percentage of Codexis revenues comes from customers in the pharmaceutical industry, which uses various enzymes in the bio-reactors in which biopharmaceutical therapies are manufactured. Several bio-pharma companies of various sizes also license Codexis' CodeEvolver technology platform to search for enzymes themselves.

Very recently, some observers have seen evidence which leads them to conclude that pharmaceutical giant Merck may be using enzymes supplied by Codexis in the manufacture of molnupiravir, which is still in trials but which Merck is hoping will become the first pill-form oral anti-viral for treating Covid-19, described by the Wall Street Journal as potentially acting as "a kind of Tamiflu for Covid-19, dispensed to patients when they first develop symptoms, slowing the spread of the virus in the body and potentially preventing people from becoming seriously ill" (story dated 01 October 2021).

While such a development could cause significant revenues for Codexis if it is indeed true that their enzymes are used in the production of molnupiravir (and if molnupiravir is eventually approved for treatment of patients), to say nothing of the possible lives it could save and the suffering it could relieve, we do not pursue an investment process that is based on predicting such individual therapeutic successes. 

Instead, as explained at the beginning of this post and as we have written about in this blog for many years (going back indeed to 2007), we emphasize owning well-run businesses aligned with important narratives, and we believe that Codexis is an innovative company whose business lines up with an investment narrative that will play out over the the course of a decade or more and across more than one industry.

We certainly hope that molnupiravir can have a positive impact and save lives -- and we would be thrilled to learn that enzymes from Codexis are an important part of its manufacture. But we believe that investors are best served by looking to bigger trends and developments -- which we call narratives -- and these individual successes along the way can serve as confirmation that a narrative is correct and that it will help people in many additional ways over the years ahead.

* At the time of publication, the principals of Taylor Frigon Capital Management owned securities issued by Codexis (CDXS). 

Previous companies featured in our long-running "Have you heard of this company?" series include:

and
(among many others)**

** At the time of publication, the principals of Taylor Frigon Capital Management owned securities issued by Tractor Supply Company (TSCO), Vapotherm (VAPO), Vuzix (VUZI), Kornit (KRNT), Boot Barn (BOOT), and Carvana (CVNA).


Disclosures: Please remember that past performance may not be indicative of future results. Different types of investments involve varying degrees of risk, and there can be no assurance that the future performance of any specific investment, investment strategy, or product (including the investments and/or investment strategies recommended or undertaken by Taylor Frigon Capital Management LLC (“Taylor Frigon”), or any non-investment related content, made reference to directly or indirectly in this blog will be profitable, equal any corresponding indicated historical performance level(s), be suitable for your portfolio or individual situation, or prove successful. Due to various factors, including changing market conditions and/or applicable laws, the content may no longer be reflective of current opinions or positions. Moreover, you should not assume that any discussion or information contained in this blog serves as the receipt of, or as a substitute for, personalized investment advice from Taylor Frigon. To the extent that a reader has any questions regarding the applicability of any specific issue discussed above to his/her individual situation, he/she is encouraged to consult with the professional advisor of his/her choosing. Taylor Frigon is neither a law firm nor a certified public accounting firm and no portion of the blog content should be construed as legal or accounting advice. A copy of the Taylor Frigon’s current written disclosure Brochure discussing our advisory services and fees is available upon request. If you are a Taylor Frigon client, please remember to contact Taylor Frigon, in writing, if there are any changes in your personal/financial situation or investment objectives for the purpose of reviewing/evaluating/revising our previous recommendations and/or services, or if you would like to impose, add, or to modify any reasonable restrictions to our investment advisory services.

Tuesday, October 5, 2021

The Disease, the Cure, and the New Cure

Most people who are paying attention recognize that things in the world are not going particularly well these days.  We certainly recognize this and are challenged with helping our clients manage through the vast amount of data and information that comes out each day in order that they can make sound financial decisions.  In difficult times it is our long-held belief that sticking to your discipline in investing is crucial.  In fact, an investor's very survival depends on it, in our view. 


As such, we would be remiss for not pointing out when things go awry, and we did just that in March of 2020 with our blog post entitled "Time For A Pushback".  We later followed up in April 2020 with "Still Pushing Back".  We urge our clients and others to read those posts if you haven't already.  We fully stand by all we said in those articles, despite at the time receiving some pretty negative feedback.


Today, another sage voice in the world of economics, Brain Wesbury, posted in his blog an article in which he gives an overview of our current economic circumstances brought about largely by the response to the COVID virus.  In "The Cost of Lockdowns", Brian outlines the myriad problems caused by the exact types of actions we highlighted almost a year and a half ago.  Unfortunately, it is going to take years to undo the damage that has been done, and, as we said in our pieces, the most vulnerable of the world's population are the ones who are most negatively impacted.  This is extremely sad and unfortunate, but it is important to keep one's wits about oneself and stay focused on the challenges ahead.  


Well-managed, innovative businesses will still succeed -- and in many cases thrive -- while navigating these challenges.  We would argue that these companies are the bright lights that will help guide the way back from the precipice.  It is our intention to stay fully invested in such companies, and continue to seek out new ones that will also drive the effort.  This is the "New Cure" that is needed.  And it is on its way, as we have now added a plethora of new companies in the past year and a half, reversing the "8000-to-4000 problem" (the decline in the number of publicly-listed companies on US exchanges) that we have lamented at length over the last several years.  


We now stand at a count over 5,800 public companies on US exchanges.  Thanks to a little-understood vehicle called the "special purpose acquisition corporation" (SPAC), we are witnessing a resurgence in new innovative public companies for the first time in years.  This increase in new company formation and growth is what leads us out of this malaise (NOT a guarantee), and we see no reason this trend can't continue.   And it can't happen soon enough!

Disclosures: Please remember that past performance may not be indicative of future results. Different types of investments involve varying degrees of risk, and there can be no assurance that the future performance of any specific investment, investment strategy, or product (including the investments and/or investment strategies recommended or undertaken by Taylor Frigon Capital Management LLC (“Taylor Frigon”), or any non-investment related content, made reference to directly or indirectly in this blog will be profitable, equal any corresponding indicated historical performance level(s), be suitable for your portfolio or individual situation, or prove successful. Due to various factors, including changing market conditions and/or applicable laws, the content may no longer be reflective of current opinions or positions. Moreover, you should not assume that any discussion or information contained in this blog serves as the receipt of, or as a substitute for, personalized investment advice from Taylor Frigon. To the extent that a reader has any questions regarding the applicability of any specific issue discussed above to his/her individual situation, he/she is encouraged to consult with the professional advisor of his/her choosing. Taylor Frigon is neither a law firm nor a certified public accounting firm and no portion of the blog content should be construed as legal or accounting advice. A copy of the Taylor Frigon’s current written disclosure Brochure discussing our advisory services and fees is available upon request. If you are a Taylor Frigon client, please remember to contact Taylor Frigon, in writing, if there are any changes in your personal/financial situation or investment objectives for the purpose of reviewing/evaluating/revising our previous recommendations and/or services, or if you would like to impose, add, or to modify any reasonable restrictions to our investment advisory services.